Language: BG BG
← Back to results
Recruiting NCT06828458

Determining Elements of Anti-Fungal Immunity in BURN Patients

Conditions: Burn

Sponsor: Assistance Publique - Hôpitaux de Paris

trial.available_in: БГ
Overview
Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.
Who can participate
Inclusion Criteria: Burn patients * Adult patients ≥ 18 years old * Admission \< 4 days following burn injury * Total burn surface Area ≥ 15% * Non opposition of the patient or his/her relatives to the research * Affiliation to social security or any health insurance Exclusion Criteria: * Pregnancy * Opposition of the patient or his/her relatives * Decision not to resuscitate or to limit or stop active therapies
Interventions
Biological sampling
OTHER
Locations 1
France (1)
Hôpital Saint Louis AP-HP
Paris
Technical details
Status
Recruiting
Study type
OBSERVATIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
23.04.2025
Completion date
23.10.2030
Registry ID
NCT06828458
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.